Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia

Inclusion Criteria: * Age ≥ 18 and ≤ 75 years, Male and female patients. * Diagnosis of PNH based on flow cytometry showing \>10% granulocyte clone size during the screening period. * Stable use of Anti-C5 antibody at least 6 months prior to enrollment. * Hemoglobin level \< 10 g/dL at screening. Exclusion Criteria: * Hereditary or acquired complement deficiency. * Active primary or secondary immunodeficiency. * History of splenectomy, bone marrow/hematopoietic stem cell or solid organ transplants. * History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis. * Patients with laboratory evidence of bone marrow failure (reticulocytes \< 100x109/L, or platelets \< 30x109/L or neutrophils \< 0.5x109/L). * Active systemic infection within 2 weeks prior to study drug administration. * History of serious comorbidities that have been determined to be unsuitable for participation in the study. * Pregnant or Lactating women.